Eurofins Strengthens Its Leading Analytical Testing Footprint in Brazil with the Acquisition of ASL Análises Ambientais
27 December 2016 - 7:00PM
Business Wire
Regulatory News:
Eurofins Scientific (Paris:ERF) (EUFI.PA), the global leader in
food and environment testing, announces that it has acquired ASL
Análises Ambientais (“ASL”), one of the leading environment testing
service providers in Brazil.
As one of the largest environment testing service providers in
the domestic market, ASL serves consulting and industrial companies
across Brazil. The company employs about 150 staff and expects to
generate revenues in excess of BRL 25m in 2016, with EBITDA margin
already at Group objective.
As one of the first signatories of the United Nations Framework
Convention on Climate Change (UNFCCC)1, Brazil has one of the
broadest environmental legislations in the world, although
enforcement has been sometimes less strong outside of São Paulo.
Adoption of regulations by other states in the country should drive
further growth in the market. The acquisition of ASL reinforces
Eurofins’ leading domestic footprint to leverage its expertise in
helping companies comply with existing, as well as future
regulations.
Comment from Dr. Gilles Martin, Eurofins CEO: “ASL,
together with Anatech, which we acquired in 2014, expands Eurofins’
footprint to become the largest environment testing service
provider in Brazil. This transaction reinforces our local footprint
and complements our leading position in the domestic food testing
market. In return, ASL will have access to the Group’s entire
portfolio of competencies, logistics and clients, which should
allow it to further expand market share.”
For more information, please visit
www.eurofins.com.
Notes for the editor:
Eurofins – a global leader in bio-analysis
Eurofins believes it is the world leader in food, environment
and pharmaceutical products testing and that it is also one of the
global independent market leaders in certain testing and laboratory
services for agroscience, genomics and discovery pharmacology and
for supporting clinical studies. In addition, Eurofins is one of
the significant emerging players in specialty clinical diagnostic
testing in Europe and the USA.
With 25,000 staff in more than 250 laboratories across 39
countries, Eurofins offers a portfolio of over 130,000 validated
analytical methods for evaluating the safety, identity,
composition, authenticity, origin, traceability and purity of
biological substances and products, as well as for innovative
clinical diagnostic. The Group provides its customers with
high-quality services, accurate results on time and expert advice
by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by
expanding both its technology portfolio and its geographic reach.
Through R&D and acquisitions, the Group draws on the latest
developments in the field of biotechnology and analytical chemistry
to offer its clients unique analytical solutions and the most
comprehensive range of testing methods.
As one of the most innovative and quality oriented international
players in its industry, Eurofins is ideally positioned to support
its clients’ increasingly stringent quality and safety standards
and the expanding demands of regulatory authorities and healthcare
practitioners around the world.
The shares of Eurofins Scientific are listed on the Euronext
Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg
ERF FP).
Important disclaimer:
This press release contains forward-looking statements and
estimates that involve risks and uncertainties. The forward-looking
statements and estimates contained herein represent the judgement
of Eurofins Scientific’ management as of the date of this release.
These forward-looking statements are not guarantees for future
performance, and the forward-looking events discussed in this
release may not occur. Eurofins Scientific disclaims any intent or
obligation to update any of these forward-looking statements and
estimates. All statements and estimates are made based on the
information available to the Company’s management as of the date of
publication, but no guarantee can be made as to their validity.
1 UNFCCC
http://unfccc.int/essential_background/convention/status_of_ratification/items/2631.php
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161227005084/en/
Eurofins BrazilEdison de Fraia, +55 19 2107 5500Managing
Directoredisonfraia@eurofins.comorInvestor RelationsEurofins
Scientific+ 32 2 766 1620ir@eurofins.com
Enerplus (NYSE:ERF)
Historical Stock Chart
From Sep 2024 to Oct 2024
Enerplus (NYSE:ERF)
Historical Stock Chart
From Oct 2023 to Oct 2024